Title | McEwen - Cardiac differentiation |
Date Submitted | March 2012 |
Submitted by - | Sunita D’Souza |
Adapted from - | Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008 May 22;453(7194):524-8. Epub 2008 Apr 23. AND SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. 2011. Nature Biotechnology, 29, 1011–1018 (2011) |
Contributors - | Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, Henckaerts E, Bonham K, Abbott GW, Linden RM, Field LJ, Keller GM. AND Nicole C Dubois, April M Craft, Parveen Sharma, David A Elliott, Edouard G Stanley, Andrew G Elefanty, Anthony Gramolini & Gordon Keller |
Affiliation(s) - | Mount Sinai School of Medicine, New York, NY 10029 |
To direct the differentiation of human embryonic stem cells (ESCs) to the cardiac lineage, Lei Yang et al., showed that the combination of BMP4 and activin A will promote cardiac development in human ESC cultures8. However, the stage at which these pathways function in the establishment of this lineage was not defined. Using the protocol developed here, the combination of activin A and BMP4 at stage 1 induces a primitive-streak-like population and mesoderm, as demonstrated by the upregulation and transient expression of T (brachyury) and WNT3A—genes known to be expressed in these populations in the mouse. At stage 2, the WNT inhibitor DKK1 is added to specify cardiac mesoderm and VEGF is included to promote the expansion and maturation of the KDR+ population. bFGF is added again at day 8 of differentiation to support the continued expansion of the developing cardiovascular lineages. Dubois et al., went on to optimize concentration of BMP4, ACTA to increase the efficiency of differentiation (Sunita, the characterization of different BMP/Activin signaling to induce primitive streak populations was described in Steve’s Cell Stem Cell paper, which would be the correct reference here). She also identified a unique cell surface marker referred to as SIRPA that tracks the specification and the expansion of the cardiac progenitor.
Caption : Analysis of mouse and human embryonic stem cell differentiation cultures indicate the existence of a cardiovascular progenitor respresenting one of the earliest stages in mesoderm specification to the cardiovascular lineages (1,2). Induction with combinations of Activin A, bone morphogenetic protein 4 (BMP4), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and dickkopf homolog 1 (DKK1) in serum free media generates a KDRlow/c-Kitneg population that displays cardiac, endothelial and vascular smooth muscle potential (2). The following schematic outlines a staged protocol for generating cardiovascular progenitors from hESCs.
Reagent | Company | Cat # | |
---|---|---|---|
1. | StemPro | Invitrogen | 10828-028 |
Knockout Serum Replacement | Invitrogen | 10828-028 | |
2. | DMEM/F12 | (Cellgro | 10-092-CV |
Penicillin/Streptomycin | Invitrogen | 15070-063 | |
3. | Glutamine | Invitrogen | 25030-081 |
4. | Ascorbic acid | Sigma | A-4544 |
Collagenase B | Sigma | T-4799 | |
5. | Monothioglycerol (MTG) | Sigma | # M-6145 |
6. | Trypsin | Sigma | T4799 |
7. | EDTA 0.5 M (pH 8) | Sigma | E6635-100G |
8. | PBS (without Ca2+, Mg2+) | (Cellgro | 21-031-CM |
9. | +/- Matrigel (1:1) * | BD | 354230 |
10. | Collagenase Type 1 | Sigma | C0-130 |
11. | Fetal Calf serum | Gemini Biologicals | 100106 |
12. | DNAse I | Calbiochem | 260913 |
13. | Transferrin | Roche | 4038377 |
14. | hBMP-4 | R&D Systems | 314-BP |
15. | hbFGF | R&D Systems | 233-FB |
16. | hVEGF | R&D Systems | 293-VE |
17. | ActivinA | R&D Systems | 338-AC |
18. | Dkk | R&D Systems | 1096-DK |
19. | hBMP-4 | R&D Systems | 314-BP |
20. | Dorsomorphin | ToCris | 3093 |
21. | collagenase type II | Invitrogen | 17101-015 |
22. | Hanks solution | Invitrogen | 14170 |
23. | Taurin -10mM | Sigma | 491330 |
24. | EGTA – 0.1mM | N | E0396 |
25. | anti-SIRPA–IgG-phycoerythrin-Cy7 clone SE5A5; BioLegend; 1:500 | Biolegend | MS-295-P1 |
26. | anti-cardiac isoform of cTNT (clone 13-11 | NeoMarkers; 1:400 | MS-295-P1 |
27. | anti-IgG1k - phycoerythrin-Cy7 (clone MOPC-21, 1:500 | Biolegend | 400129 |
L-ASCORBIC ACID (AA) (SIGMA # A-4544)
Prepare a stock solution of 5 mg/mL in cold TC-H2O. Leave on ice and vortex periodically until completely dissolved. Filter sterilize, aliquot and store at -20ºC. Use once and discard.
MONOTHIOGLYCEROL (MTG) (SIGMA# M-6145)
The amounts of MTG indicated in our protocols are recommended concentrations. However, it is important to test each new batch of MTG as there is variability between them. MTG should be aliquoted (1 mL) and stored frozen (-20ºC). When aliquots are thawed, they can be used for several experiments and then discarded. Aliquoting of MTG is strongly recommended as it minimizes the amount of oxidation due to repeated opening.
TRANSFERRIN (ROCHE# 10 652 202 )
The amounts of Transferrin indicated in our protocols are recommended concentrations. However, it is important to test each new batch of transferrin as there is variability between them. It should be aliquoted (2 mL) and stored at 4ºC.
COLLAGENASE B (Cat # 11 08 831 001)
Final Conc. | For 1 Liter | ||
---|---|---|---|
Collagenase B | (Sigma# T-4799) | 1mg/ml | 1 g |
DMEM/F12 + Glut +P/S | (Cellgro# 10-092-CV) | 100% | 1000 mL |
Collagenase II – Overnight solution for the dissociation of EBs: Collagenase type II (1 mg/ml; Worthington) was dissolved in Hanks solution (NaCl, 136 Mm; NaHCO3, 4.16 mM; NaPO4, 0.34 mM; KCl, 5.36 mM; KH2PO4, 0.44 mM; dextrose, 5.55 mM; HEPES, 5 mM), filtered, aliquoted and frozen.
Collagenase II –dissociation solution. Collagenase type II was dissolved in Hanks solution: taurin, 10 mM, EGTA 0.1 mM, BSA 1 mg/ml, filtered, aliquoted and frozen.
(A) COLLAGENASE TYPE 1 (SIGMA# C-0130)
Final Conc. | For 500ml | ||
---|---|---|---|
Collagenase Type 1 | (Sigma# # C-0130) | 2mg/ml | 1 g |
PBS1X Ca/Mg | (CellGro # 21-030-CM) | 100% | 400 mL |
FCS | Gemini Biologicals # 100106 | 20% | 100 mL |
Collagenase Type 1 is mainly used for dissociation of the embryoid bodies.
(B) DNASE I (VWR, Cat # 80510-412, 10MU)
STEMPRO 34 (Invitrogen# 10639-011)
Stempro 34 is sold as a kit with 2 components. The supplement is kept at -20oC and the liquid media at 4oC. When combined, the media is unstable, therefore, we use it for a maximum of 2 weeks. If not used right away, we store the medium as 50mL aliquots and supplement them as needed. The supplement is frozen as 1.3mL aliquots which is the amount required for 50mL. of medium.
Final Conc. | For 500ml | |
---|---|---|
STEMPRO 34 Kit | 500 mL | |
Penicillin/Streptomycin P/S | 1% | 5 mL |
MATRIGEL (REDUCED FACTOR) (BD# 354230)
Each batch of matrigel has its own unique levels of endotoxin and protein concentrations. We find that the endotoxin levels should not be higher than 2 endotoxin units/mL and the protein levels should range between 7 to 10 mg/mL. If the protein levels are higher than this you may need to dilute the matrigel more than 1:1. This is determined by observing the hESC colony morphology and the ability of the hESCs to differentiate into the lineage required of them.
Caution: When working with matrigel, all tubes, plates and pipettes should be pre-chilled, as matrigel solidifies at room temperature.
MATRIGEL1:1 PREPARATION
(C) TRYPSIN-EDTA
Catalogue # |
Final Conc. | For 1 Liter | |
---|---|---|---|
Trypsin | Sigma T4799 | 0.25% | 2.5 g |
EDTA 0.5 M (pH 8) | Sigma E6635-100G | 1 mM | 2 mL |
PBS (without Ca2+, Mg2+) | Invitrogen 14190-136 | 100% | 1000 mL |
(D) STOP MEDIUM
Catalogue # |
Final Conc. | For 40 Liter | |
---|---|---|---|
hESC WASH Medium | See (E) below | 50% | 20 mL |
FCS | Gemini 100106 | 50% | 20 mL |
+/- Matrigel (1:1) * | See Matrigel Prep | 1:800 | 100 uL |
(E) hESC WASH MEDIUM
Catalogue # |
Final Conc. | For 500 Liter | |
---|---|---|---|
Supplemented | See Supplemented | 95% | 475 mL |
DMEM/F12 | DMEM /F12 media below | ||
KnockoutTM Serum Replacement | Invitrogen 10828-028 | 5% | 25 mL |
SUPPLEMENTED DMEM/F12
Final Conc. | For 500 Liter | |
---|---|---|
DMEM/F12 | 500 mL | |
Penicillin/Streptomycin | 1% | 5 mL |
Glutamine | 1% | 5 mL |
(F) AGGREGATION MEDIUM
Stock Conc. |
Final Conc. | per mL | For 50 mL | |
---|---|---|---|---|
STEMPRO 34 | 50 mL | |||
Glutamine | 100x | 1% | 10uL | 500ul |
Transferrin | 30mg/mL | 150ug/mL | 5uL | 250ul |
Ascorbic Acid | 5mg/mL | 50ug/mL | 10ul | 500ul |
MTG | 26λ/2mLs | 3ul | 150 mL | |
BMP4* | 10ug/mL | 1ng/mL | 0.1uL | 5uL |
*Bmp4 concentration may vary according to lot# or the hES cell line used.
(G) INDUCTION 1 MEDIUM
Stock Conc. |
Final Conc. | per mL | For 50 mL | |
---|---|---|---|---|
STEMPRO 34 | 50 mL | |||
Glutamine | 100x | 1% | 10uL | 500ul |
Transferrin | 30mg/mL | 150ug/mL | 5uL | 250ul |
Ascorbic Acid | 5mg/mL | 50ug/mL | 10ul | 500ul |
MTG | 26λ/2mLs | 3ul | 150 mL | |
BMP4* | 10ug/mL | 10ng/mL | 1uL | 50uL |
bFGF | 10ug/mL | 2.5ng/mL | 0.25uL | 12.5uL |
Activin A | 10ug/mL | 6ng/mL | 0.6uL | 30 uL |
(I) INDUCTION 2 MEDIUM
Stock Conc. |
Final Conc. | per mL | For 50 mL | |
---|---|---|---|---|
STEMPRO 34 | 50 mL | |||
Glutamine | 100x | 1% | 10uL | 500ul |
Transferrin | 30mg/mL | 150ug/mL | 5uL | 250ul |
Ascorbic Acid | 5mg/mL | 50ug/mL | 10ul | 500ul |
MTG | 26λ/2mLs | 3ul | 150 mL | |
VEGF | 5ug/mL | 5ng/mL | 1uL | 50uL |
Dkk | 50ug/mL | 150ng/mL | 3uL | 150 uL |
(J) INDUCTION 3 MEDIUM*
Stock Conc. |
Final Conc. | per mL | For 50 mL | |
---|---|---|---|---|
STEMPRO 34 | 50 mL | |||
Glutamine | 100x | 1% | 10uL | 500ul |
Transferrin | 30mg/mL | 150ug/mL | 5uL | 250ul |
Ascorbic Acid | 5mg/mL | 50ug/mL | 10ul | 500ul |
MTG | 26λ/2mLs | 3ul | 150 mL | |
VEGF | 5ug/mL | 520ng/mL | 1uL | 50uL |
bFGF | 10ug/mL | 10ng/mL | 1uL | 50 uL |
*NB: Dkk not required beyond Day 8
The formation of EBs is the first important step in the differentiation of hESC. This is best achieved by culturing small aggregates of hESCs in miminal amounts of BMP-4 for 24 hours. At this stage, BMP-4 functions to promote the survival of the hESCs.
T0-T1: Generation of embryoid bodies (EBs)
T1-4: Induction 1 (Stage 1)
* For some cell lines start Stage II from Day3
T4-T8 (OR Day D3 – D5): Induction 2 (Stage II)
* For some lines addition of 100ng/ml of Noggin and 0.6uM of SB431542 from D4-D5 helps to increase the specification of cardiac progenitors. In some cases the addition of 0.5uM –1uM of Dorsomorphin does the same.
Notes
Mesoderm induction and cardiovascular progenitor specification in the EBs should be evaluated by flow cytometric analysis, monitoring the cells for expression of KDR and CD117 (c-kit). As each hESC line has its own unique kinetics, it is best to define the CV progenitor stage based on the profile seen below, rather than by time in culture. The CV progenitor stage is defined by the appearance of a population that expresses an intermediate level of KDR in the absence of CD117 (KDRlow/CD117neg). EBs at this stage also contain a KDRneg/CD117pos and a KDRhigh/CD117pos. The KDRlow/CD117neg profile is typically detected in hESC-derived EBs at day 5, however the kinetics of this induction vary slightly from lab to lab (and cell line to cell line…) and should be determined. Alternatively as shown in the second figure below, the first cells specified to the cardiomyocyte lineage can also be tracked by SIRPA expression (Biolegend 323808). SIPRA tracks with NKX2.5 and starts being expressed between days 7-10, depending on the efficiency of differentiation and the cell line used. and over 90% of the SIRPA+ progenitors express cardiac Troponin (this number may even be higher and the cTnT-negative cells in the SIRPA+ fraction may be sorting contaminations to some extent, however, this is difficult to prove…).
FACS Profiles
T5 Harvest for Flow Cytometry
(Perform flow cytometric analysis from Day 4-7 to determine the optimal cardiac mesoderm induction kinetics)
If Induction Media II (containing DKK) is added to the cultures at Day 3, followed by Noggin/SB at day 4, change media at Day 5 and replace it with Induction Media II (Day 4-day8 media).
T8-T12: Induction 3 (Stage III)
To further increase efficiency SIRPA+ progenitors can be FACS sorted or separated using magnetic beads (Miltenyl). The sorted cells are cultured on gelatin coated dishes at a concentration of …….(200’000 SIRPA+ cells per 96 well) in the appropriate stage media depending on the stage of development they were sorted at. For eg. EBs sorted at Day 8 will be cultured in Induction Media III.
Dissociation procedure for day 13 and older EBs. EBs generated from hPSC differentiation cultures were incubated in collagenase type II (1 mg/ml; Worthington) in Hanks solution (NaCl, 136 Mm; NaHCO3, 4.16 mM; NaPO4, 0.34 mM; KCl, 5.36 mM; KH2PO4, 0.44 mM; dextrose, 5.55 mM; HEPES, 5 mM) overnight at 25 °C with gentle shaking. On the following day, the equivalent amount of dissociation solution (in Hanks solution: taurin, 10 mM, EGTA 0.1 mM, BSA 1 mg/ml, collagenase type II 1 mg/ml) was added to the cell suspension and the EBs were pipetted gently to dissociate the cells. After dissociation, cells were centrifuged (1,000 r.p.m., 5 min), filtered and used for analysis. For EBs older than 40 d, additional treatment with 0.25% trypsin/EDTA is often required to obtain complete dissociation to single-cell suspensions.
T12-T20: Induction 3 (Stage III continued)
Intracellular Troponin T Staining Protocol A. Harvest EBs:
Staining for intracellular TroponinT (use between 100,000-300,000 cells)
Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, Henckaerts E, Bonham K, Abbott GW, Linden RM, Field LJ, Keller GM. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008 May 22;453(7194):524-8.
Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, Ellis J, Keller G. 2011. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell. Feb 4;8(2):228-40.
Nicole C Dubois, April M Craft, Parveen Sharma, David A Elliott, Edouard G Stanley, Andrew G Elefanty, Anthony Gramolini & Gordon KellerSIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. 2011. Nature Biotechnology, 29, 1011–1018 (2011)
Special thanks to Marion Kennedy for putting this protocol together.
This page was last modified on October 18, 2012